0001209191-16-142357.txt : 20160921
0001209191-16-142357.hdr.sgml : 20160921
20160921212954
ACCESSION NUMBER: 0001209191-16-142357
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160919
FILED AS OF DATE: 20160921
DATE AS OF CHANGE: 20160921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kaye Edward M. MD
CENTRAL INDEX KEY: 0001522780
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 161896579
MAIL ADDRESS:
STREET 1: 3450 MONTE VILLA PARKWAY
CITY: BOTHELL
STATE: WA
ZIP: 98011
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-09-19
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001522780
Kaye Edward M. MD
215 FIRST STREET
SUITE 415
CAMBRIDGE
MA
02142
1
1
0
0
President, CEO & CMO
Common Stock
2016-09-19
4
M
0
13000
8.28
A
89983
D
Common Stock
2016-09-19
4
S
0
13000
50.00
D
76983
D
Common Stock
2016-09-19
4
M
0
947
5.40
A
77930
D
Common Stock
2016-09-19
4
S
0
947
50.00
D
76983
D
Common Stock
2016-09-19
4
M
0
10405
5.40
A
87388
D
Common Stock
2016-09-19
4
S
0
10405
50.00
D
76983
D
Non-Qualified Stock Options (right to buy)
13.90
2016-09-19
4
M
0
13000
8.28
D
2012-06-20
2012-06-20
Common Stock
13000
80358
D
Incentive Stock Options (right to buy)
5.40
2016-09-19
4
M
0
947
5.40
D
2013-04-24
2022-04-24
Common Stock
947
0
D
Non-Qualified Stock Options (right to buy)
5.40
2016-09-19
4
M
0
10405
5.40
D
2013-04-24
2022-04-24
Common Stock
10405
0
D
This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
/s/David Tyronne Howton, as Attorney-in-Fact for Edward M. Kaye
2016-09-21